Form 4: Syndax Pharmaceuticals CFO Acquires Shares and Stock Options

Keith A. Goldan, CFO of Syndax Pharmaceuticals, reports acquisition of common stock and stock options.

Summary

• On February 5, 2025, Keith A. Goldan, the Chief Financial Officer of Syndax Pharmaceuticals Inc., acquired 18,500 shares of common stock and 23,400 shares of common stock.
• These shares were awarded as restricted stock units (RSUs).
• One third of the 18,500 shares vest annually.
• The vesting of the 23,400 shares is contingent upon the achievement of pre-established performance metrics.
• Goldan also acquired 110,500 stock options with an exercise price of $14.65, vesting monthly over four years, expiring on 02/05/2035.
• Following these transactions, Goldan directly owns 94,523 shares of Syndax Pharmaceuticals Inc. common stock and 110,500 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports transactions by an insider, which could be seen as a positive sign of confidence, but without further context, it's difficult to draw strong conclusions.

Positives

• The CFO's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.
• The vesting of a portion of the RSUs being tied to performance metrics aligns the CFO's interests with those of the shareholders.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term commitment from the CFO to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation practices in the pharmaceutical industry, used to incentivize executives and align their interests with shareholders.
• The vesting schedules and performance-based conditions are typical features of such grants, designed to retain talent and drive performance.
• Comparing the size of the grant to those of CFOs at comparable companies (e.g., Arcus Biosciences, Blueprint Medicines) would provide further context.

Stakeholder Impact

• The transactions reported in the Form 4 filing may influence investor sentiment regarding Syndax Pharmaceuticals Inc.

Key Dates